Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt reflects on a year marked by promising clinical trial results and a landmark partnership with Merck. He highlights progress in developing treatments for autoimmune diseases and anticipates milestones for the year ahead.
Copyright 2024 – Finance News Network
Source: Finance News Network
06 May 2020 - Acorn Capital Investment Fund Ltd. (ASX: ACQ) Head of Research and Portfolio Manager for the Consumer Discretionary, Consumer Staples and Information Technology sectors, Robert Bruce talks about the listed investment company, the fund’s composition and outlook for the next 6 months and longer term.
Read More18 Jan 2021 - Tourism Accommodation Australia CEO Michael Johnson discusses the impact of COVID-19 on hotels across Australia.
Read More25 Jul 2024 - Alex Dorsch - CEO & Managing Director - Chalice Mining (ASX:CHN) is advancing the Gonneville Project—a major 2020 discovery in Western Australia with critical metals like platinum, nickel, and copper—towards development. The project boasts a tier-1 Mineral Resource Estimate, significant land in the new West Yilgarn Ni-Cu-PGE Province, and has earned multiple awards, including the 2023 Thayer Lindsley Award.
Read More28 Nov 2022 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses the LAG-3 landscape, the company's portfolio of therapies, encouraging data from the 2022 SITC conference and the outlook for 2023.
Read More16 Aug 2021 - BluGlass Limited (ASX:BLG) Executive Chair, James Walker and Chief Technology and Operations Officer, Dr Ian Mann discuss the company’s world-first demonstration of working tunnel junction laser diodes created using remote plasma chemical vapour deposition (RPCVD) technology.
Read More27 Sep 2021 - LBT Innovations Limited (ASX:LBT) CEO and Managing Director Brent Barnes discusses the appointment of a US distributor for the company's APAS Independence instrument.
Read More25 Feb 2020 - Noxopharm Limited (ASX:NOX) Chief Medical Officer, Dr Gisela Mautner, talks about results from the company's LuPIN trial in prostate cancer, evaluating its lead product candidate, Veyonda, in combination with 177Lu-PSMA-617, a radiopharmaceutical therapy, in 56 patients with late-stage prostate cancer.
Read More21 Sep 2023 - Brendan Stats - CEO - TMK Energy Limited (ASX:TMK) is a gas exploration company listed on the Australian Stock Exchange. TMK holds a 67% interest in the Gurvantes XXXV Project located in the South Gobi Basin of Mongolia and also holds a 20% interest in the Talisman Depp Project containing the Napoleon Structure located in the Barrow-Dampier Sub-basin.
Read More03 Sep 2020 - Hazer Group (ASX:HZR) CEO & Managing Director, Geoff Ward talks about FY20 achievements, its final investment decision for its Commercial Development Plant to process low emissions hydrogen gas and high purity graphite production from biogas, development and commercial programs.
Read More13 May 2024 - Lithium Universe's CEO Alex Hanly unveils the company's strides in 2024 towards North American lithium independence.
Read More
